ReachMD

Episodes 1-3 of 3

• 

  RestartResume

  Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going

  CME/CE

  Targeting HER3 in Breast and Lung Cancers: Where We Are and Where We Are Going

  • 

    

    Jennifer Caudle, DO

    Peer

  • 

    

    Sara A. Hurvitz, MD, FACP

    Peer

  • 

    

    Narjust Florez, MD

    Peer

  0.50 credits

• 

  RestartResume

  The Oncogenic Significance – and Promise – of HER3 in Pharmacotherapy

  CME/CE

  The Oncogenic Significance – and Promise – of HER3 in Pharmacotherapy

  • 

    

    Helena Yu, MD

    Peer

  • 

    

    Makenzi Evangelist, MD

    Peer

  0.50 credits

• 

  RestartResume

  Better Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer

  CME/CE

  Better Early Than Late: CDK4/6 Inhibition in HR+, HER2- Early Breast Cancer

  • 

    

    Hope S. Rugo, MD, FASCO

    Peer

  • 

    

    Peter Schmid, FRCP, MD, PhD

    Peer

  0.50 credits